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Abstract 
Dipeptidyl peptidase IV (DPP-IV also referred to as CD-26) is a serine protease enzyme with 
remarkable diagnostic and prognostic value in a variety of health and disease conditions. 
Herein, we describe a simple and real-time colorimetric assay for DPP-IV/CD-26 activity 
based on the aggregation of gold nanoparticles (AuNPs) functionalized with the peptide 
substrates: Gly-Pro-Asp-Cys (GPDC) or Val-Pro-ethylene diamine-Asp-Cys (VP-ED-DC). 
Cleavage of the substrates by DPP-IV resulted in aggregation of the AuNPs with 
accompanying colour change in the solution from red to blue that was monitored using either 
a UV-visible spectrophotometer or by the naked eye. Factors, such as pH, ionic strength and 
the structure of the substrate that influence the cleavage reaction in solution were 
investigated. The effects of potential interference from serum proteins (lysozyme, thrombin 
and trypsin) on the analytical response were negligible. The detection limits when GPDC or 
VP-EN-DC functionalized AuNPs were used for DPP-IV assay were 1.2 U/L and 1.5 U/L, 
respectively. The VP-EN-DC method was preferred for the quantitative determination of 
DPP-IV activity in serum because of its wide linear range 0 - 30 U/L compared to 0-12 U/L 
for the GPDC assay. Recoveries from serum samples spiked with DPP-IV activity, between 
5-25U/L, and using the VP-EN-DC modified AuNPs method ranged between 83.6-114.9%. 
The two colorimetric biosensors described here are superior to other conventional methods 
because of their simplicity, stability, selectivity and reliability.  
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1. Introduction  
Dipeptidyl peptidase IV/CD26 (DPP4/ DPP-IV) is a type II transmembrane serine protease 
glycoprotein belonging to the S9 prolyl oligopeptidase family [1] and capable of splitting N-
terminal dipeptides from polypeptide substrates with proline in the penultimate position, 
thereby acting on a variety of compounds such as chemokines, neuropeptides, peptide 
hormones and incretins. The enzyme is implicated in immune regulation, oncological, 
neurodegenerative and inflammatory processes, and also in nutritional control and 
nociception [2,3]. The focus of ongoing research is in the development of drugs which target 
DPP-IV production for the therapeutic management of type II diabetes and its use as a 
biomarker for the management of heart failure [4]. It has been suggested that the 
measurement of DPP-IV activity can be used as a diagnostic and prognostic marker for 
various inflammatory disorders, tumours and haematological malignancies [5–9]. Therefore, 
there is demand for simple, selective and sensitive assays that can be used to measure the 
activity of DPP-IV in health and disease. 
 To date, the most commonly used methods for the determination of DPP-IV 
enzymatic activity are based on the deployment of chromogenic, fluorogenic,
,
 bioluminescent 
and electrochemical [10–13] sensors (Table 1). Although sensitive, most fluorogenic probes 
suffer from poor aqueous solubility and therefore, require the use of organic co-solvents 
which have been reported to reduce enzyme activity and thus limit their application to cell-
free assays [14]. A further drawback with the use of the current chromogenic substrates is 
that they contain over reactive leaving groups, which render them easily susceptible to non-
enzymatic cleavage by interfering proteins in biological samples [15]. 
 Nanoplasmonic colorimetric assays are highly sensitive because of the high extinction 
coefficients of gold nanoparticles (AuNPs), 10
2 
-10
3
 times higher than those of conventional 
colored dyes [16].Using thiol chemistry, recognition substrates, e.g. peptides with cysteine 
residues, alkane thiolate or tiopronin [17–19] can be coupled to the AuNPs surface to form a 
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colloidal solution whose stability is affected in the presence of the enzyme resulting in the 
aggregation of the AuNPs with accompanying colour change. Label-free colorimetric assays 
in which the substrate reporter molecule is not covalently attached to the AuNPs but through 
electrostatic and hydrophobic interactions have also been reported for the detection of 
thrombin [20] and alkaline phosphatase [21]. Detection of enzymatic activity by using metal 
(typically gold) nanoparticle based colorimetric assays is an attractive alternative to 
traditional enzymatic assays because color changes are visible to the naked eye. This color 
change caused by direct or indirect induced AuNP aggregation forms the basis for the 
colorimetric detection. A variety of enzymes (lipase, protease, kinase and DNAse) have been 
detected using this approach [22–25]. 
 Of critical importance to this type of application is to ensure that the colloidal solution 
is stable and the resultant aggregation is triggered by the analyte and not due to any non-
specific changes in the solution. In order to improve the stability of the colloidal solution, 
Lévy and co-workers, (2004) designed a pentapeptide sequence (CALNN)  using a 
combinatorial approach in order to produce an extremely stable, water soluble peptide ligand, 
which has been used as an additional stabilizer in colorimetric platforms for the detection of a 
variety of analytes [26,27]. Takeshi et al.,
 
2010, in an attempt to produce a stable colloid, 
explored a different approach in which the reduction of the gold salt and functionalization 
with phosphorylated dipeptide pTyr-Arg substrate occurred simultaneously in the presence of 
0.1M HEPES buffer (pH 7.2) to detect alkaline phosphatase activity [28]. However, with this 
approach, the colloidal solution may not be stable enough to withstand changes caused by 
matrix constituents in complex biological samples. 
 Most of the AuNP-based assays for the measurement of enzyme activity are largely based on 
the AuNPs aggregation initiated by the enzyme reaction.
 
The length of the substrate is one of 
the essential parameters that are of crucial importance to the performance of the assay based 
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on functionalized AuNPs. A well-designed substrate confers steric stabilization on the AuNP 
colloidal solution, and  provides optimum distances between the P-AuNPs to allow the 
enzyme easy access to the substrate.  
Recently, Xia et al. used unmodified Au NPs as a colorimetric probe to measure DPP-IV 
activity [29]. Their method was based on the design of peptide sequence (Arg-Pro-Arg) with 
2 binding tags to crosslink unmodified Au NPs. In their method, the Au NPs were not 
functionalized with the peptide substrate making their method prone to possible interferences 
from the sample matrix. More importantly, their two-stage method is not amenable to real-
time monitoring of enzyme activity.  
Herein we investigate and compare the performances of Au NPs functionalized separately 
with two designed peptide probes [(Gly-Pro-Asp-Cys (GPDC) and Val-Pro-NH-(CH2)2-NH-
Asp-Cys (VP-EN-DC)] in the development of a rapid and simple colorimetric assay for the 
measurement of DPP-IV activity. This method is a novel non-crosslinking AuNP-based 
colorimetric method for detection of DPP-IV activity. 
2. Materials and methods 
2.1 Reagents and Materials 
 The peptide Gly-Pro-Asp-Cys (~ 90%) pure was purchased from Thermo Fisher 
Scientific Co. Ltd (Germany), Val-Pro-NH-(CH2)2-NH-Asp-Cys (> 95%) pure was purchased 
from Cambridge Research Biochemicals (UK). DPP-IV enzyme from porcine kidney was 
purchased from Merck Chemicals (Germany). Human lysozyme, trypsin from porcine 
pancreas, hydrogen tetrachloroaurate(III) (HAuCl4.3H2O), 99.99% pure, and sodium citrate 
dihydrate (Na3C6H5O7.2H2O), 99% pure, were purchased from Sigma-Aldrich Co. Ltd (UK) 
and used without further purification. Thrombin from bovine plasma was purchased from GE 
HealthCare (UK). Normal human serum control was purchased from Thermo Scientific. 
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The DPP-IV solutions were prepared in 50mM Tris buffer solution of pH 8.3. A 10 mМ 
citrate buffer solution at pH 6 was used to dissolve the GPDC peptide, VP-EN-DC was 
dissolved in 50 mМ Glycine buffer solution (pH 10).All solutions were prepared using 
deionized water with a resistivity of 18.2 MΩ cm-1 prepared with a Milli-Q Academic 
Purification equipment from Millipore (UK). 
2.2 Preparation of citrate-capped AuNPs  
 Citrate AuNPs (∼15 nm) diameter was prepared by citrate reduction of HAuCl4 [30]. 
Briefly, 10 ml of 38.8 mM sodium citrate dihydrate at 50-60ºC was added to 100 ml of 1 mM 
boiling HAuCl4 under vigorous stirring to form a ruby red colored solution instantaneously. 
After cooling, the solution was filtered through a 0.22 µm Millipore syringe filter to remove 
any precipitate, the pH was adjusted to 7.4 using 0.5 M NaOH solution, and the filtrate was 
stored at 4ºC.  
2.3 Preparation of peptide-capped AuNPs bioconjugate (P-AuNPs) 
 The Gly-Pro-Asp-Cys conjugated AuNPs were prepared by addition of an aqueous 
solution of 2 mM peptide in citrate buffer pH 6, to the solution of 8 nM citrate AuNPs (based 
on an extinction coefficient of ~1.61×10
8
 M
-1
 cm
-1
 at 520 nm for AuNPs) in a volume ratio of 
1 to 10. After overnight reaction at room temperature, excess peptides were removed by 
centrifugation (13000 rpm, 30 min at 4
o
C) using an Eppendorf centrifuge (Eppendorf, 
Germany), the pelleted AuNPs were resuspended in deionized water and stored at 4
o
C. Val-
Pro-NH-(CH2)2-NH-Asp-Cys modified AuNPs were prepared by the same procedure with 
slight modification to the rate and time of centrifugation used for separating the modified 
AuNPs (14500 rpm, 20 min at 4
 o
C). The pellets were resuspended in Tris buffer pH 8.3 and 
stored at 4ºC. 
2.4 Instrumentation for gold nanoparticle characterization 
 The ultraviolet-visible (UV-vis) absorption spectra were recorded on a microplate 
reader (Tecan 2000, San Francisco, USA) using transparent 96 well microplates (Nunclon, 
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Thermo Scientific, UK). ESI-Mass spectra of the peptides were obtained on an API-150EX 
MS single quadrupole LC/MS system (Applied Biosystems). Dynamic light scattering (DLS), 
(Malvern Zetasizer Nano-ZS) for sizing measurements were carried out using a 10mm 
disposable sizing cuvette and the particle size measurements were performed in triplicate. 
The XPS spectra were obtained on a VG Escalab 210 Photoelectron Spectrometer. The X-ray 
source was a non-monochromated Al Kα source (1486.6eV), operated with an X-ray 
emission current of 20 mA and an anode high tension (acceleration voltage) of 12 kV. The 
freeze-dried sample was placed on a standard sample stud employing double-sided adhesive 
tape and the take-off angle was fixed at 90º relative to the sample plane.  
 Transmission electron microscope (TEM) images were taken on a CM200 Tecnai 
TF20. Field emission gun TEM (FEGTEM) operated at an accelerating voltage of 200 kV 
and equipped with a Gatan Orius SC600A CCD camera to capture images of the AuNPs. 
Samples were prepared by placing a drop of the functionalized-AuNPs solution on a copper 
grid. The films on the TEM grids were allowed to dry for 5 minutes under a heat bulb.  
2.5 Colorimetric assay of DPP-IV activity 
 To perform the colorimetric DPP-IV assays, 100 µL aliquots of the modified AuNPs  
solutions were mixed in the wells of a transparent 96-well microtiter plate with the enzyme 
dissolved in 50mM Tris buffer pH 8.3. The contents were gently mixed using a plate shaker 
at 200 rpm for 60 seconds, and the 96 well plates were incubated at 37 °C for 15 minutes. 
The UV-vis absorption spectrum of each solution was recorded in absorbance scan mode 
from 400-900nm. To study the reaction dynamics, the P-AuNPs were exposed to a series of 
activities of DPP-IV ranging from 2 to 40 U/L and the aggregation of modified AuNPs was 
monitored by recording the changes in the absorption spectra. 
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  3. Results and Discussion 
The first of the two peptide substrates, GPDC was designed to mimic the structure of the 
chromogenic substrate Gly-Pro-p-nitroanilide, which is one of the most frequently used for 
DPP-IV detection. The rationale for the choice of this sequence include the presence of the 
following: (i)  the enzyme cleavage site in the peptide (NH2-GP) for DPP-IV, as the enzyme 
functions selectively on a dipeptide sequence that contain a protonated amino group (Lambier 
et al., 2003), (ii) cysteine (C) as anchor to facilitate immobilization of the peptide to the 
AuNP surface, (iii) aspartic acid (D) in order to impart a negative charge on the peptide thus 
enhance the stability of the colloidal solution. In the second peptide, VP-EN-DC ethylene 
diamine was incorporated into the structure in order to act as a spacer, so that possible steric 
hindrance caused by the curvature of the AuNPs is reduced. A schematic diagram of the 
enzymatic reaction followed by AuNP aggregation is shown in Fig.1.  
The UV-Vis spectra of the as-prepared AuNPs stabilized with citrate ions, and functionalized 
with either peptide substrates is shown in Fig. 2a. Confirmation of the peptide substrate 
binding was obtained from X-ray photoelectron spectroscopy (XPS) measurements. The S 2p 
peak at approximately 161.8 eV is consistent with the formation of a thiolate linkage, in 
comparison with the S in the free thiol which appears at 164.8 eV as shown in Fig. 2b.  
 DLS measurements showed that the peptide modified AuNPs have an average 
hydrodynamic diameter of 36.5 nm when functionalized with GPDC peptide and 45.1 nm for 
VP-EN-DC in comparison to 21.9 nm for the citrate stabilized nanoparticles. This difference 
in diameter is indicative of the surface functionalization of the AuNPs with each peptide. The 
extent of the AuNPs surface modification was assessed by zeta potential measurements, 
which changed upon the addition of each of the substrate. The zeta potential shifted from -
19±1.5 mV for citrate stabilized AuNPs to -28±4mV for VP-EN-DC capped and -23.5 ± 2.5 
mV for GPDC-capped AuNPs, respectively. Solutions of the functionalized AuNPs were 
stable for several months when stored at 4°C (Supplementary information Fig. S1). 
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 The addition of DPP-IV/CD 26 to each substrate functionalized AuNPs solution 
resulted in a colour change from red to pale blue. The absorbance of the surface plasmon 
resonance band (SPR) at 525nm decreased with accompanying band broadening between 
600-800 nm as shown in Figures 3a and 3b for both VP-EN-DC and GPDC substrates, 
respectively indicative of the formation of aggregates. The color intensity increased with 
higher DPP-IV activity as more of the peptide substrates were cleaved by DPP-IV causing 
further aggregation. Furthermore, increasing DPP-IV activity was associated with the gradual 
shift of absorbance band to a higher wavelength with resultant colour change and band 
broadening for both peptide substrates. Results from transmission electron microscopy 
(TEM) measurements show that the dispersed substrate functionalized AuNPs aggregate in 
the presence of DPP-IV with an increase in the average hydrodynamic diameter (Figure 4a-
d).  Dynamic light scattering (DLS) data are consistent with the TEM results, which showed 
that with the addition of DPP-IV, their sizes after aggregation changed from 36.5 and 45.1nm 
for both the substrates GPDC and VP-EN-DC functionalized Au NPs to 342 nm and 413 nm, 
respectively. The broad band obtained for the VP-EN-DC functionalized Au NPs is indicative 
of the formation of  large Au NPS aggregates. 
 In order to establish the optimum time for enzymatic hydrolysis of the functionalized 
AuNPs, changes in UV-visible spectra were measured at different time points. The time-
dependent absorbance changes at Abs642/Abs522 for GPDC functionalized AuNPs with 
different enzyme activities are shown in Supporting Information Fig. S2a. DLS 
measurements were used to follow the changes in the size of AuNPs over time following 
enzyme addition. The DLS data show that the hydrodynamic size of the AuNPs gradually 
increased after the addition of the enzyme and plateaus after about 10 minutes (Supporting 
Information Fig. S2b). 
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 To further assess the selectivity of the method, experiments were performed with 
potential interfering proteins and enzymes such as trypsin, thrombin, lysozyme human serum 
albumin (HSA) and denatured DPP-IV, to examine whether this treatment with any of these 
compounds could trigger AuNPs aggregation. As shown in Fig. 5a, the proteases thrombin 
and trypsin and the non-protease HSA and lysozyme did produce signals that were 
commensurate with the background, revealing that our assay is selective and enzyme activity-
dependent. The same experiments were performed with the VP-EN-DC functionalized AuNP, 
and comparable results were observed (Figure 5`b). In order to test that the same response is 
not obtained without modification of the  AuNPs, different concentrations of DPP-IV (0, 2.5, 
5, 10, 15, 20, and 25 U/L) were added to the unmodified citrate Au-NP suspensions and no 
color change was observed thus confirming that DPP-IV alone does not induce aggregation 
of the AuNP (Supporting Information Fig. S3). 
 For quantitative DPP-IV/ CD26 activity measurement, the activities of DPP-IV (2.5, 
5, 10, 15, 20, 25, 30, 35 and 40) in Tris buffer of were used to calibrate the assay. Linear 
regression analysis showed very good linearity for both AuNPs assays (r
2 
= 0.9924 for GPDC 
AuNPs, r
2
 = 0.9761 for VP-EN-DC AuNPs) as shown in Figs 5c,d. The GPDC functionalized 
AuNPs displayed a narrow linear range 2–12 U/L with the signal levelling out at higher 
activities. The detection limit (LOD) of 1.2 U/L DPP-IV, based on 3σb/slope, where σb was 
the standard deviation of the blank samples. A wider calibration range was obtained with VP-
EN-DC modified AuNPs, and the calibration plots displayed a good linear relationship 
between the red shifts of the LSPR peak (Δλ max) and DPP-IV activities in the range of 0 - 
40 U/L, with a LOD of 1.5 U/L DPP-IV.  
 Normal human DPP-IV activity in serum range between 17 - 52.6 U /L [31]. The 
developed colorimetric VP-EN-DC AuNPs assay is suitable for the qualitative and 
quantitative determination of DPP-IV activity in human serum samples. For this purpose, we 
9 
 
spiked human serum samples with varying DPP-IV activities (5, 10, 15, 20 and 25 U/L) to 
investigate the analytical properties of the colorimetric assay (see Figure S4 in the Supporting 
Information).  Table 2 shows that the recoveries of the practical samples are in the range 
83.6% to 114.9%. The very good recoveries and precision values are an indication of the 
reliability of the proposed method for detection of DPP-IV in biological samples.  
          The stability of the colloidal system is mainly governed by steric hindrance and 
electrostatic repulsion forces between the charged peptide capping ligands. The DPP-IV 
protease recognizes the sequence of Xaa-Pro-, and cleaves at the C-terminus of the 
underlined proline residue, shortens the length of the peptide arm and thus the distance 
between particles decreases which in turn affects the plasmon resonance of the functionalized 
nanoparticles due to the removal of steric barriers between the particles, thus resulting in 
irreversible AuNPs aggregation. Overall, both substrates proved to be useful candidates for 
the detection and measurement of DPP-IV activity with high sensitivity and selectivity. 
However, the additional advantage in using VP-EN-DC for quantitative determination is that 
it offers a wider linear range that covers the levels of DPP IV activity in serum. It is probable 
that the incorporation of the spacer arm in its design provides extra space for the hydrolytic 
enzyme cleavage resulting in the formation of larger AuNPs aggregates as can be seen from 
the results of the DLS measurement of the hydrodynamic radius.  
4. Conclusions 
 
 We have designed and developed a novel, simple real-time and one-step colorimetric 
detection method for the measurement of DPP-IV enzymatic activity based on the 
aggregation of functionalized AuNPs in the presence of the enzyme. The relevance of this 
nanoparticle-based assay resides in the fact that visual detection or simple instrumentation 
can be used for this analysis. In principle, aggregation of GPDC or VP-EN-DC functionalized 
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AuNPs can be used to measure the activity of DPP-IV after hydrolysis by the enzyme. The 
aggregation of AuNPs induced a gradual colour change that can be observed by the naked 
eye. The detection limits for GPDC and VP-EN-DC were 1.2 and 1.5 U/L, respectively 
making them suitable for the detection of DPP-IV activity, but the VP-EN-DC based assay is 
preferred because of the wider linear calibration range. More importantly, the developed VP-
EN-DC method has been successfully applied to the detection of DPP-IV activity in spiked 
serum samples. The developed method offers a new approach for developing simple, cheap, 
reliable and sensitive sensors for DPP-IV detection. 
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 Figures and Captions:  
 
Fig.1 Schematic representation of the working principle for measurement of DPP-IV/ CD26 
activity. DPP-IV hydrolyzes the amide bond between Xaa-Pro and aspartic acid or ethylene 
diamine. (In color)  
Fig.2 (a) UV-Vis absorption spectra of citrate stabilized AuNPs (blue), P- modified AuNPs 
(red), (b) Detection of covalent thiolate - gold bond (S-Au) by high resolution XPS spectra. A 
Weak signal of a free thiol (R-SH) appeared at (164.8 eV) while the sulphur atom that bound 
to Au revealed prominent signal at a binding energy of (161.8 eV). Error bar represents the 
standard deviation (n = 3), c) Average Hydrodynamic radius of AuNPs before and after 
modification with GPDC and VP-EN-DC peptides separately d) zeta potential measurements 
of bare AuNPs (black), GPDC-capped AuNPs (blue) and VP-EN-DC capped AuNPs verified 
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the surface functionalization of the particles. Error bar represents the standard deviation (n = 
3). (In color) 
Fig.3 (a) UV−vis Absorption spectra of  VP-EN-DC capped AuNPs & b) GPDC capped 
AuNPs after incubation with different activities of DPP-IV. The DPP-IV/CD-26 activity 
ranged from 0 to 40 U/L. (Inset: Solution color changes after the addition of DPP-IV (right to 
left) 2.5, 5, 7.5, 10, 15, 20, 25, 30 and 40  U/L to the VP-EN-DC AuNPs assay. (In color) 
 
 Figure 4 TEM images of (a,b) GPDC-AuNPs  and (c, d) VP-EN-DC-AuNPs without DPP-
IV (panels (a) and (c)) and (b, d)with DPP-IV (20 U/L)  . All samples were suspended in 
Tris (pH 8.3, 50 mM) at 37 °C. Scale bar = 100 nm. (In color) 
 
Figure 5 Response of the modified AuNP solution incubated with 20 U/L of DPP-IV 
compared to effect produced by  other enzymes, proteins such as lysozyme (1µg/mL), 
thrombin (20 U/mL), trypsin (20 µg/L) and Denatured DPP-IV (heating at 80 °C 15 minutes) 
under the same conditions. Error bar represents the standard deviation (n = 3) when mixed 
with a) GPDC functionalized AuNPs, b) VP-EN-DC functionalized AuNPs 
c) Calibration curve of Abs642/Abs522 versus the different activities of DPP-IV incubated with 
(GPDC functionalized AuNPs). (Inset: Expanded linear region for DPPIV activity in the 
range of 2-12 U/L). Error bar represents the standard deviation (n = 3). d) Calibration curve 
of Abs700/Abs525 versus the different activities DPP-IV incubated with (VP-EN-DC 
functionalized AuNPs). 
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Figure 3 
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Figure 4 
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Figure 5 
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Table 1 Comparison of the assay sensitivity as defined by the limit of detection (LOD) and 
limit of quantification (LOQ) of colorimetric, fluorometric and luminescent DPP-IV assays. 
 (GP: glycyl proline; Me: methoxy; NA: naphthylamide; AMC: amino methyl coumarin; Fc: 
Ferrocene) 
Substrate LOD (U/L) LOQ (U/L) Type of Assay 
Gly-Pro-p-nitroanilide 1.56 2.92  Colorimetric [32] 
Gly-Pro-4-Me-β-NA) 0.10 0.26  Fluorometric [32] 
Gly-Pro-AMC 0.18 0.27  Fluorometric [32] 
DPPIV-Glo™ 
Protease*  
Fc-Tyr-Pro-Phe-Phe-
NH2 
 
Arg-Pro-Arg Au NP
 
0.035 
 
3.9 * 10
-5
 
 
 
0.07 
 
 
 
0.040 
 
0.5 * 10
-3
  
 
 
0.1 
 
 
 
Luminescent [12] 
 
Electrochemical [33] 
 
 
Colorimetric [29] 
 
 
 
 
    
 
Table 2 Analytical results for DPP-IV  in spiked serum samples 
 
Add (U/L) Found (U/L)* Recovery (%) RSD (%) 
5 5.04± 0.19 100.8 3.23 
10 8.36± 0.23 83.6 2.37 
15 15.89± 0.33 105.9 2.1 
20 22.99± 0.91 114.9 4 
25 26.77± 0.34 107 1.31 
* Average of three determinations ± standard deviation. 
 
Highlights  
 Two colorimetric assays based on enzyme peptide substrates functionalized gold 
nanoparticles for the measurement of dipeptidyl peptidase IV/CD26 (DPP-IV) 
activity have been developed. 
 Aggregation of the gold nanoparticles in the presence of DPP IV with resultant 
color change followed by UV/Vis spectrometry was used to measure the activity of 
the enzyme. 
 The analytical performance of the two designed enzyme peptide substrates, Gly-
Pro-Asp-Cys (GPDC) and Val-Pro-ethylene diamine-Asp-Cys (VP-ED-DC), 
respectively were investigated. 
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 A spacer moiety (ethylene diamine) was introduced in one of the sequences to 
enhance the distance of hydrolysable moiety from gold nanoparticle surface and to 
investigate its effect on aggregation of the gold nanoparticles. 
 Quantitative determination of activity can be achieved by plotting absorbance 
ratio at two fixed wavelengths with DPP-IV activity. 
 Excellent recoveries were obtained in spiked serum samples. 
 The developed biosensors were simple, fast and reliable and thus suitable for point 
of care and real-time DPP-IV activity measurements.  
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